InnoCare Pharma Limited (HKG:9969)
Hong Kong
· Delayed Price · Currency is HKD 10.52
+0.16 (1.54%)
Apr 24, 2025, 4:08 PM HKT
InnoCare Pharma Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Operating Revenue | 1,008 | 736.99 | 624.12 | 1,043 | 1.36 | Upgrade
|
| Other Revenue | 1.8 | 1.55 | 1.28 | - | - | Upgrade
|
| Revenue | 1,009 | 738.54 | 625.4 | 1,043 | 1.36 | Upgrade
|
| Revenue Growth (YoY) | 36.68% | 18.09% | -40.04% | 76368.70% | 9.38% | Upgrade
|
| Cost of Revenue | 138.44 | 128.44 | 143.4 | 65.67 | - | Upgrade
|
| Gross Profit | 871.01 | 610.1 | 482.01 | 977.37 | 1.36 | Upgrade
|
| Selling, General & Admin | 588.49 | 551.01 | 613.66 | 436.89 | 157.58 | Upgrade
|
| Research & Development | 814.61 | 757.25 | 648.7 | 721.58 | 402.77 | Upgrade
|
| Other Operating Expenses | 11.13 | -26.76 | -49.84 | 1.42 | - | Upgrade
|
| Operating Expenses | 1,416 | 1,282 | 1,213 | 1,160 | 560.35 | Upgrade
|
| Operating Income | -544.71 | -671.67 | -730.61 | -182.53 | -558.99 | Upgrade
|
| Interest Expense | -33.79 | -35.21 | -17.38 | -2.64 | -1.14 | Upgrade
|
| Interest & Investment Income | 178.71 | 197.9 | 136.91 | 135.21 | 98.58 | Upgrade
|
| Earnings From Equity Investments | - | - | - | -0.6 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -43.65 | -87.84 | -290.56 | 57.14 | 108.29 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.38 | 6.57 | -0.82 | 17.59 | -38.61 | Upgrade
|
| EBT Excluding Unusual Items | -443.83 | -590.24 | -902.46 | 24.16 | -391.87 | Upgrade
|
| Gain (Loss) on Sale of Investments | -30.46 | -53.96 | 8.73 | 6.73 | - | Upgrade
|
| Asset Writedown | -0.1 | - | - | - | - | Upgrade
|
| Other Unusual Items | 21.81 | - | - | -51.01 | - | Upgrade
|
| Pretax Income | -452.59 | -644.21 | -893.73 | -20.12 | -391.87 | Upgrade
|
| Income Tax Expense | 0.26 | 1.43 | - | 46.56 | - | Upgrade
|
| Earnings From Continuing Operations | -452.86 | -645.63 | -893.73 | -66.68 | -391.87 | Upgrade
|
| Minority Interest in Earnings | 12.22 | 14.37 | 7.13 | 2.13 | 0.47 | Upgrade
|
| Net Income | -440.63 | -631.26 | -886.59 | -64.55 | -391.4 | Upgrade
|
| Net Income to Common | -440.63 | -631.26 | -886.59 | -64.55 | -391.4 | Upgrade
|
| Shares Outstanding (Basic) | 1,695 | 1,706 | 1,478 | 1,366 | 968 | Upgrade
|
| Shares Outstanding (Diluted) | 1,695 | 1,706 | 1,478 | 1,366 | 968 | Upgrade
|
| Shares Change (YoY) | -0.67% | 15.46% | 8.15% | 41.21% | 321.19% | Upgrade
|
| EPS (Basic) | -0.26 | -0.37 | -0.60 | -0.05 | -0.40 | Upgrade
|
| EPS (Diluted) | -0.26 | -0.37 | -0.60 | -0.05 | -0.40 | Upgrade
|
| Free Cash Flow | -443.78 | -920.14 | -860.91 | -2.71 | -423.51 | Upgrade
|
| Free Cash Flow Per Share | -0.26 | -0.54 | -0.58 | -0.00 | -0.44 | Upgrade
|
| Gross Margin | 86.28% | 82.61% | 77.07% | 93.70% | 100.00% | Upgrade
|
| Operating Margin | -53.96% | -90.95% | -116.82% | -17.50% | -40981.38% | Upgrade
|
| Profit Margin | -43.65% | -85.47% | -141.76% | -6.19% | -28694.65% | Upgrade
|
| Free Cash Flow Margin | -43.96% | -124.59% | -137.66% | -0.26% | -31049.41% | Upgrade
|
| EBITDA | -477.69 | -611.8 | -692.12 | -167.2 | -556.92 | Upgrade
|
| EBITDA Margin | -47.32% | -82.84% | -110.67% | -16.03% | - | Upgrade
|
| D&A For EBITDA | 67.02 | 59.87 | 38.49 | 15.33 | 2.07 | Upgrade
|
| EBIT | -544.71 | -671.67 | -730.61 | -182.53 | -558.99 | Upgrade
|
| EBIT Margin | -53.96% | -90.95% | -116.82% | -17.50% | - | Upgrade
|
| Revenue as Reported | 1,009 | 738.54 | 625.4 | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.